| Name | Title | Contact Details |
|---|
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.
Hexagon Labs is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
John's Hopkins Healthcare LLC is a Glen Burnie, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
InAssist is a El Segundo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since its beginning in 1902` Cedars-Sinai has evolved to meet the healthcare needs of one of the most diverse regions in the nation` continually setting new standards for quality and innovation in patient care` research` teaching and community service. Today` Cedars-Sinai is widely known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai receives consistent recognition for our excellence. Our awards include; being named one of America`s Best Hospitals by U.S. News & World Report` receiving the National Research Corporation`s Consumer Choice Award 19 years in a row for providing the highest-quality medical care in Los Angeles` achieving the longest-running Magnet designation for nursing excellence in California` and being recognized as The Advisory Board Company`s 2017 Workplace of the Year` an award Cedars-Sinai has won three years in a row. This annual award recognizes hospitals and health systems nationwide that have outstanding levels of employee engagement. Cedars-Sinai is a leader in the clinical care and research of heart disease` cancer and brain disorders` among other areas. Pioneering research achievements include using cardiac stem cells to repair damaged hearts` developing minimally invasive surgical techniques and discovering new types of drugs to target cancer more precisely. Cedars-Sinai also impacts the future of healthcare through education programs that encompass everything from highly competitive medical residency and fellowship programs to a biomedical science and translational medicine PhD program` advanced training for nurses and educational opportunities for allied health professionals. Most notably` Cedars-Sinai demonstrates a longstanding commitment to strengthening the Los Angeles community through wide-ranging programs that improve the health of its most vulnerable residents.